Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: A dose-ranging clinical study

Annals of Oncology

Volumn 15, Issue 2, 2004, Pages 330-337

  Eisenberg, P ^a   MacKintosh, F R ^b   Ritch, P ^c   Cornett, P A ^d   Macciocchi, A ^e  

^a California Cancer Care   (United States)

^b VA Sierra Nevada Health Care System   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HELSINN HEALTHCARE SA   (Switzerland)

Author keywords

5 Hydroxytryptamine type 3 receptor antagonist; Chemotherapy; Dose ranging; Emesis; Nausea; Palonosetron

Indexed keywords

ANTIEMETIC AGENT; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACARBAZINE; NITROSOUREA DERIVATIVE; PALONOSETRON; SEDATIVE AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PLASMA HALF LIFE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; QUINUCLIDINES; VOMITING;

EID: 1342267601     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh047     Document Type: Article

References (28)

1. Hasler WL. Serotonin receptor physiology. Relation to emesis. Dig Dis Sci 1999; 44 (Suppl): 108S-113S.
2. 3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 1998; 55: 173-189.
3. ASHP Commission on Therapeutics. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999; 56: 729-764.
4. 3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000; 18: 163-173.
5. 3 receptor antagonists. Expert Opin Pharmacother 2000; 1: 207-223.
6. Aapro MS, Thuerlimann B, Sessa C et al. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 2003; 14: 291-297.
7. Koeller JM, Aapro MS, Gralla RJ et al. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 2002; 10: 519-522.
8. 3 receptors in vitro. Br J Pharmacol 1995; 114: 851-859.
9. 3 receptors. Drug Dev Res 1993; 28: 87-93.
10. Van Wijngaarden I, Tulp MTM, Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 1990; 188: 301-312.
11. 3 receptors in the small intestine of rats. Jpn J Pharmacol 1997; 73: 357-360.
12. Hutt AJ, Tan SC. Drug chirality and its clinical significance. Drugs 1996; 52 (Suppl 5): 1-12.
13. 3 receptor antagonist, in vivo. Br J Pharmacol 1995; 114: 860-866.
14. Zofran® [package insert]. Research Triangle Park, NC, USA: Glaxo-SmithKline; 2001.
15. Anzemet® [package insert]. Bridgewater, NJ, USA: Aventis Pharmaceuticals; 2000.
16. Kytril® [package insert]. Nutley, NJ, USA: Roche Laboratories Inc.; 2000.
17. Serotone® [prescribing information]. Tokyo, Japan: Torii Pharmaceutical Co. Ltd; 2001.
18. Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-109.
19. Piegorsch WW. Multiple comparisons for analyzing dichotomous response. Biometrics 1991; 47: 45-52.
20. 3 receptor antagonists the same? Eur J Cancer 1992; 28A (Suppl 1): S6-S11.
21. 3 antagonist, for the prevention of chemotherapy-induced nausea and vomiting. Invest New Drugs 1990; 8: 407-409.
22. Smith IE. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group. Eur J Cancer 1990; 26 (Suppl 1): S19-S23.
23. Soukop M. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group. Eur J Cancer 1990; 26 (Suppl 1): S15-S19.
24. Hesketh PJ, Gandara DR, Hesketh AM et al. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer 1996; 4: 141-146.
25. Seynaeve C, Schuller J, Busser K et al. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicenter, double-blind, randomised, parallel group study. Ondansetron Study Group. Br J Cancer 1992; 66: 192-197.
26. Kris MG, Grunberg SM, Gralla RJ et al. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 1994; 12: 1045-1049.
27. Beck TM, Hesketh PJ, Madajewicz S et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. Clin Oncol 1992; 10: 1969-1975.
28. 3-receptor antagonist: palonosetron (RS 25259-197). Proc Am Soc Clin Oncol 2001; 20: 400a (Poster 1595).